Business
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of
About this update from Actuate Therapeutics, Inc.
[{"type":"image","alt":"Actuate Therapeutics","displaySize":"","headline":null,"caption":"Actuate Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/8600bbc6448d867dc281bd537c05e09e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/33fX_k368HBbxSS0OT6lrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8600bbc6448d867dc281bd537c05e09e","width":300,"height":117}},"lazy":false},{"type":"text","content":"Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.","length":100,"tagName":"p"},{"type":"text","content":"Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease","length":166,"tagName":"p"},{"type":"text","content":"CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in Clinical Cancer Research from a Phase II study (NCT05010629) evaluating elraglusib in combination with carboplatin or cisplatin (with or without sequential pembrolizumab priming) in patients with advanced, metastatic salivary gland cancers, including adenoid cystic carcinoma and other subtypes. The peer-reviewed paper (PMID: 41065505), entitled “Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma,” is available here.","length":931,"tagName":"p"},{"type":"text","content":"Despite decades of research, there are no approved systemic cytotoxic or targeted therapies available for the treatment of recurrent and metastatic salivary gland cancer. While some treatments have shown modest activity in certain molecular subgroups, such as HER2 (Human Epidermal Growth Factor Receptor 2)-overexpressing, androgen receptor-overexpressing, or NTRK (Neurotrophic Tyrosine Receptor Kinase)-fused tumors, most patients lack actionable therapeutic targets. Exp...